A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
Haematologica
; 107(6): 1454-1459, 2022 06 01.
Article
in En
| MEDLINE
| ID: mdl-34788987
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
/
COVID-19
/
Lymphoma
Limits:
Humans
Language:
En
Journal:
Haematologica
Year:
2022
Type:
Article